Summary of results at Week 24 from included trials for the overall population. (DOCX 40Â kb
Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S1. SF-36 domain scores by MDA responder status, mean (SD) and p-values. (DOCX 15 kb
<p>Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies f...
Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb
ACR response rates and NNT at Week 24 among biologic-naĂŻve population. (DOCX 13Â kb
PASI response rates and NNT at Week 24 among biologic-naĂŻve population1. (DOCX 12Â kb
Incremental cost per responder over 24Â weeks among the overall PsA population. (DOCX 13Â kb
Incremental cost per responder over 24Â weeks among biologic-naĂŻve population. (DOCX 13Â kb
Incremental cost per responder over 24 weeks among the biologic-naïve population. (A) Incremental co...
Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...
Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...
Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...
Figure S1. Examples of baseline and follow-up MRI and HR-pQCT images. Figure S2. Single patient anal...
Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Figure S1. Showing study design, Table S1. Presenting independent ethics committees (IECs) or instit...
Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S1. SF-36 domain scores by MDA responder status, mean (SD) and p-values. (DOCX 15 kb
<p>Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies f...
Summary of results at Week 24 from included trials among biologic-naĂŻve population. (DOCX 36Â kb
ACR response rates and NNT at Week 24 among biologic-naĂŻve population. (DOCX 13Â kb
PASI response rates and NNT at Week 24 among biologic-naĂŻve population1. (DOCX 12Â kb
Incremental cost per responder over 24Â weeks among the overall PsA population. (DOCX 13Â kb
Incremental cost per responder over 24Â weeks among biologic-naĂŻve population. (DOCX 13Â kb
Incremental cost per responder over 24 weeks among the biologic-naïve population. (A) Incremental co...
Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...
Table S1. Least squares (LS) mean change from baseline in composite endpoint scores (full analysis s...
Table S2. Change from baseline in composite endpoint scores by minimal disease activity (MDA) respon...
Figure S1. Examples of baseline and follow-up MRI and HR-pQCT images. Figure S2. Single patient anal...
Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Figure S1. Showing study design, Table S1. Presenting independent ethics committees (IECs) or instit...
Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...
Table S1. SF-36 domain scores by MDA responder status, mean (SD) and p-values. (DOCX 15 kb
<p>Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies f...
DOI
Add to ORKG